Aditxt (ADTX) said Monday that its Pearsanta unit has begun enrolling patients in a prospective clinical study evaluating the Mitomic Endometriosis Test, a blood-based diagnostic tool for endometriosis.

The study, which will enroll up to 1,000 participants, is intended to evaluate the clinical performance of the Mitomic Endometriosis Test compared with laparoscopic diagnosis, Aditxt said.

Shares of Aditxt were up more than 6% in recent premarket activity Monday.